AMGN / LGND / Nplate: Sales of Nplate® (romiplostim) increased 28 percent to $77 million in the third quarter of 2011 versus $60 million in the third quarter of 2010. These increases were driven primarily by global demand. http://wwwext.amgen.com/media/media_pr_detail.jsp?releaseID=1620695